Home › Funds › Novo Holdings A/S › DYN
Novo Holdings A/S position in DYN
DYNE THERAPEUTICS INC · Health Care
Novo Holdings A/S reported holding 1,376,164 shares of DYN (DYNE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$22.2M, representing 1.49% of its reported portfolio and ranking #20 among its reported holdings. Novo Holdings A/S has disclosed DYN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Novo Holdings A/S's DYN position evolved
Novo Holdings A/S first disclosed a stake in DYN in Q2 2026 at 960,394 shares (US$21.3M). The position peaked in Q3 2026 at 1,376,164 shares, worth US$22.2M. Across 2 filings, Novo Holdings A/S increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,376,164 shares valued at US$22.2M — an increase of 415,770 shares quarter over quarter.. Notable position changes include a 43% increase in Q3 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 960.39K | $21.33M | New |
| Q3 2026 | 1.38M | $22.17M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DYN and 13F data
DYN (DYNE THERAPEUTICS INC) is a Health Care company. 34 other funds we track also report a position in DYN — the largest reported positions include Vestal Point Capital, LP (US$99.9M), TCG Crossover Management, LLC (US$74.3M), Frazier Life Sciences Management, L.P. (US$62.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DYN
- Vestal Point Capital, LP 6.20M sh · $99.88M · Q3 2026
- TCG Crossover Management, LLC 4.62M sh · $74.35M · Q3 2026
- Frazier Life Sciences Management, L.P. 3.85M sh · $62.07M · Q3 2026
- FCPM III SERVICES B.V. 3.59M sh · $57.78M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 3.44M sh · $55.43M · Q3 2026
- MPM BioImpact LLC 3.21M sh · $51.68M · Q3 2026
- Logos Global Management LP 3.00M sh · $48.33M · Q3 2026
- ARMISTICE CAPITAL, LLC 2.68M sh · $43.14M · Q3 2026
- Sofinnova Investments, Inc. 2.51M sh · $40.45M · Q3 2026
- Siren, L.L.C. 2.43M sh · $39.13M · Q3 2026
- Venrock Adviser, LLC 2.17M sh · $35.02M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 1.90M sh · $30.61M · Q3 2026
More on Novo Holdings A/S
FAQ
How long has Novo Holdings A/S held DYN?
Novo Holdings A/S has disclosed DYN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Novo Holdings A/S's current position in DYN?
As of Q3 2026, Novo Holdings A/S holds 1.38M shares of DYN (DYNE THERAPEUTICS INC), valued at $22.17M, representing 1.49% of its reported portfolio and ranking #20.
Has Novo Holdings A/S been buying or selling DYN?
In the latest 13F filing (Q3 2026), Novo Holdings A/S increased its position in DYN. The position peaked in Q3 2026 at 1.38M shares.
Which other funds hold DYN?
Other major institutional holders of DYN include Vestal Point Capital, LP, TCG Crossover Management, LLC, Frazier Life Sciences Management, L.P., among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.